Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Molecular Cancer Therapeutics

Volumn 9, Issue 11, 2010, Pages 2970-2981

  Spicakova, Tatiana ^a   O'Brien, Maureen M ^a   Duran, George E ^a   Sweet Cordero, Alejandro ^a   Sikic, Branimir I ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; SMALL INTERFERING RNA; TAU PROTEIN; VALSPODAR;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LENTIVIRINAE; MICROTUBULE; OVARY CANCER; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MODELS, BIOLOGICAL; PROTEIN ISOFORMS; RNA, SMALL INTERFERING; TAU PROTEINS; TAXOIDS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 78649648936     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0780     Document Type: Article

References (36)

1. Ring AE, Ellis PA. Taxanes in the treatment of early breast cancer. Cancer Treat Rev 2005;31:618-27.
2. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;106:2337-44.
3. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
4. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 2005;93:293-301.
5. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
6. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008;1785:96-132.
7. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80.
8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
9. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
10. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-20.
11. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
12. Wagner P, Wang B, Clark E, et al. Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 2005;4:1149-52.
13. Mimori K, Sadanaga N, Yoshikawa Y, et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 2006;94:1894-7.
14. Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta 2005;1739:91-103.
15. Black MM, Slaughter T, Moshiach S, Obrocka M, Fischer I. Tau is enriched on dynamic microtubules in the distal region of growing axons. J Neurosci 1996;16:3601-19.
16. DiTella M, Feiguin F, Morfini G, Caceres A. Microfilament-associated growth cone component depends upon Tau for its intracellular localization. Cell Motil Cytoskeleton 1994;29:117-30.
17. Gorath M, Stahnke T, Mronga T, Goldbaum O, Richter-Landsberg C. Developmental changes of tau protein and mRNA in cultured rat brain oligodendrocytes. Glia 2001;36:89-101.
18. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A 1995;92:10369-73.
19. Wei ML, Andreadis A. Splicing of a regulated exon reveals additional complexity in the axonal microtubule-associated protein tau. J Neurochem 1998;70:1346-56.
20. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res 1986;387:271-80.
21. Gao QS, Memmott J, Lafyatis R, et al. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J Neurochem 2000;74:490-500.
22. Himmler A. Structure of the bovine tau gene: alternatively spliced transcripts generate a protein family. Mol Cell Biol 1989;9:1389-96.
23. Couchie D, CMavilia C, Georgieff IS, et al. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci U S A 1992;89:4378-81.
24. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of humanmicrotubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-26.
25. Goedert M, Spillantini MG, Crowther RA. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. Proc Natl Acad Sci U S A 1992;89:1983-7.
26. Himmler A, Drechsel D, Kirschner MW, Martin DW, Jr. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 1989;9:1381-8.
27. Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron 1989;2:1389-97.
28. Lee G, Cowan N, Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain. Science 1988;239:285-8.
29. Pauwels B, Korst AE, de Pooter CM, et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 2003;51:221-6.
30. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-204.
31. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000;33:95-130.
32. Wang J, Tse SW, Andreadis A. Tau exon 6 is regulated by an intricate interplay of trans factors and cis elements, including multiple branch points. J Neurochem 2007;100:437-45.
33. Matsuno A, Takekoshi S, Sanno N, et al. Modulation of protein kinases and microtubule-associated proteins and changes in ultrastructure in female rat pituitary cells: effects of estrogen and bromocriptine. J Histochem Cytochem 1997;45:805-13.
34. Ferreira A, Caceres A. Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules. J Neurosci 1991;11:392-400.
35. Andre F, Hatzis C, Anderson K, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-7.
36. Pusztai L, Jeojg JH, Gong Y, et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 2009;27:4287-92.